Wilson Sonsini Advises Doron Therapeutics on $11 Million Series A

On November 25, 2024, Doron Therapeutics, a clinical-stage biotech company focusing on degenerative musculoskeletal conditions, announced it has raised $11 million in a Series A round to take MOTYS™ into Phase 3 clinical studies. SPRIM Global Investments (SGI), a prominent health sciences investment firm, led the round. Wilson Sonsini Goodrich & Rosati advised Doron Therapeutics on the transaction.

MOTYS™ is an intra-articular biologic drug developed for the management of symptomatic knee osteoarthritis. Data from a Phase 2 clinical trial were recently presented on podium at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria - where MOTYS™ was identified as a highly promising program to address the significant impact of debilitating osteoarthritis.

The Wilson Sonsini team that advised Doron Therapeutics included:

Corporate
Mark Solakian
Reilly Clark
Erica Wolfe Heinz
Alex Stebbins

Corporate Finance
Charlotte Kim

For more information, please see Doron Therapeutics’ press release.